Beijing SL Pharmaceutical Co Ltd (002038) — Cash Flow Reinvestment Rate
Beijing SL Pharmaceutical Co Ltd (002038) has a Cash Flow Reinvestment Rate of 0.17x as of September 2025, reinvesting CN¥11.35 Million (capex CN¥11.35 Million ) from operating cash flow of CN¥66.55 Million. See cash generation quality of Beijing SL Pharmaceutical Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Beijing SL Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2003–2025)
Historical reinvestment intensity for Beijing SL Pharmaceutical Co Ltd across 23 annual periods. For the full cash flow conversion analysis, see Beijing SL Pharmaceutical Co Ltd (002038) cash conversion ratio.
Annual Cash Flow Reinvestment Rate for Beijing SL Pharmaceutical Co Ltd (2003–2025)
Year-by-year capital reinvestment analysis for Beijing SL Pharmaceutical Co Ltd. See Beijing SL Pharmaceutical Co Ltd (002038) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.03x | CN¥265.61 Million | CN¥257.66 Million | CN¥192.97 Million | ▼ -33.1% |
| 2024 | 1.54x | CN¥347.57 Million | CN¥225.49 Million | CN¥347.38 Million | ▲ +160.9% |
| 2023 | 0.59x | CN¥271.93 Million | CN¥460.20 Million | CN¥218.36 Million | ▼ -67.3% |
| 2022 | 1.81x | CN¥703.89 Million | CN¥389.82 Million | CN¥163.49 Million | ▲ +252.7% |
| 2021 | 0.51x | CN¥237.87 Million | CN¥464.63 Million | CN¥236.91 Million | ▼ -73.9% |
| 2020 | 1.96x | CN¥816.62 Million | CN¥415.84 Million | CN¥255.95 Million | ▲ +238.9% |
| 2019 | 0.58x | CN¥385.77 Million | CN¥665.83 Million | CN¥272.78 Million | ▼ -37.8% |
| 2018 | 0.93x | CN¥451.84 Million | CN¥485.17 Million | CN¥227.37 Million | ▼ -23.1% |
| 2017 | 1.21x | CN¥460.83 Million | CN¥380.72 Million | CN¥229.65 Million | ▼ -34.6% |
| 2016 | 1.85x | CN¥734.87 Million | CN¥396.86 Million | CN¥164.21 Million | ▲ +109.2% |
| 2015 | 0.89x | CN¥446.93 Million | CN¥504.87 Million | CN¥129.68 Million | ▲ +172.6% |
| 2014 | 0.32x | CN¥151.01 Million | CN¥465.00 Million | CN¥151.01 Million | ▲ +3.1% |
| 2013 | 0.32x | CN¥109.48 Million | CN¥347.41 Million | CN¥109.48 Million | ▼ -49.3% |
| 2012 | 0.62x | CN¥247.89 Million | CN¥398.60 Million | CN¥247.89 Million | ▲ +94.6% |
| 2011 | 0.32x | CN¥73.05 Million | CN¥228.59 Million | CN¥73.05 Million | ▲ +76.8% |
| 2010 | 0.18x | CN¥43.04 Million | CN¥238.13 Million | CN¥43.04 Million | ▲ +3.5% |
| 2009 | 0.17x | CN¥30.46 Million | CN¥174.41 Million | CN¥30.46 Million | ▲ +43.7% |
| 2008 | 0.12x | CN¥23.61 Million | CN¥194.32 Million | CN¥23.61 Million | ▼ -59.7% |
| 2007 | 0.30x | CN¥26.61 Million | CN¥88.36 Million | CN¥26.61 Million | ▼ -73.3% |
| 2006 | 1.13x | CN¥64.95 Million | CN¥57.55 Million | CN¥64.95 Million | ▼ -34.0% |
| 2005 | 1.71x | CN¥81.24 Million | CN¥47.48 Million | CN¥81.24 Million | ▲ +201.6% |
| 2004 | 0.57x | CN¥17.73 Million | CN¥31.26 Million | CN¥17.73 Million | ▲ +5.5% |
| 2003 | 0.54x | CN¥16.43 Million | CN¥30.55 Million | CN¥16.43 Million | — |